Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua Armenia

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2019
Significance of <i>BRCA2</i> and <i>RB1</i> Co-loss in Aggressive Prostate Cancer ProgressionGoutam Chakraborty, Joshua Armenia, Ying Z Mazzu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2020
Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic ResponseBen Sidders, Pei Zhang, Kelly Goodwin, et al.
Cancer Research Communications|June 1, 2026
Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase 2a PLANETTE StudyRahul R Aggarwal, Antoine Italiano, Susan M Domchek, et al.
The Journal of Clinical Investigation|June 5, 2018
ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5DKazumasa Komura, Yuki Yoshikawa, Teppei Shimamura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2019
A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2)Ying Z Mazzu, Joshua Armenia, Goutam Chakraborty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2016
Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast CancerMartin G Dalin, Alexis Desrichard, Nora Katabi, et al.
Nature Genetics|July 18, 2018
Genome doubling shapes the evolution and prognosis of advanced cancersCraig M Bielski, Ahmet Zehir, Alexander V Penson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2018
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune TherapiesJames J Harding, Subhiksha Nandakumar, Joshua Armenia, et al.
European Urology|October 7, 2018
Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant ChemotherapyEugene J Pietzak, Emily C Zabor, Aditya Bagrodia, et al.
JCO Precision Oncology|October 5, 2020
Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate CancerDavid R Wise, Jeffrey A Schneider, Joshua Armenia, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2019
Significance of <i>BRCA2</i> and <i>RB1</i> Co-loss in Aggressive Prostate Cancer ProgressionGoutam Chakraborty, Joshua Armenia, Ying Z Mazzu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2020
Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic ResponseBen Sidders, Pei Zhang, Kelly Goodwin, et al.
Cancer Research Communications|June 1, 2026
Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase 2a PLANETTE StudyRahul R Aggarwal, Antoine Italiano, Susan M Domchek, et al.
The Journal of Clinical Investigation|June 5, 2018
ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5DKazumasa Komura, Yuki Yoshikawa, Teppei Shimamura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2019
A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2)Ying Z Mazzu, Joshua Armenia, Goutam Chakraborty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2016
Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast CancerMartin G Dalin, Alexis Desrichard, Nora Katabi, et al.
Nature Genetics|July 18, 2018
Genome doubling shapes the evolution and prognosis of advanced cancersCraig M Bielski, Ahmet Zehir, Alexander V Penson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2018
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune TherapiesJames J Harding, Subhiksha Nandakumar, Joshua Armenia, et al.
European Urology|October 7, 2018
Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant ChemotherapyEugene J Pietzak, Emily C Zabor, Aditya Bagrodia, et al.
JCO Precision Oncology|October 5, 2020
Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate CancerDavid R Wise, Jeffrey A Schneider, Joshua Armenia, et al.
Pageof 4